Given the early onset of resistance to BRAF inhibitors in virtually all treated patients together with the still limited success rates of immune therapy [56], there is a pressing need for efficient therapies in late stage melanoma patients, which either prevent or considerably delay drug resistance by targeting other aberrant signaling pathways. The gene discussed is BRAF; the disease is melanoma.